Since the discovery of the strong downregulatory action of PCSK9 on the LDLR [8] and CD81 [12], a protective role of PCSK9 on HCV infection of hepatocytes has been postulated [12] and thus, the treatment with monoclonal antibodies anti PCSK9 might increase the vulnerability to the infection [13]. This evidence concerns the gene PCSK9 and infection.